(Q36287599)

English

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial (English)

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Srinivasan Madhusudan

object named as

Srinivasan Madhusudan

11

0 references

object named as

Juan W Valle

1

0 references

object named as

Caroline Dive

18

0 references

David Cunningham

object named as

David Cunningham

8

0 references

4

object named as

Alison C Backen

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

author name string

Harpreet Wasan

2

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Andre Lopes

3

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Daniel H Palmer

5

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Karen Morris

6

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Marian Duggan

7

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

D Alan Anthoney

9

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Pippa Corrie

10

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Anthony Maraveyas

12

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Paul J Ross

13

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Justin S Waters

14

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Will P Steward

15

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Charlotte Rees

16

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Sandy Beare

17

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

John A Bridgewater

19

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

12 July 2015

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

16

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

967-978

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Serum tumor markers in bile duct cancer--a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Targeting PDGFR-β in Cholangiocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

A novel high-through-put assay for screening of pro-apoptotic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Mechanism of action and in vivo role of platelet-derived growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

30 September 2017

Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

29 June 2018

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

22 September 2018

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

22 September 2018

A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

22 September 2018

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

22 September 2018

Optimisation of circulating biomarkers of cell death for routine clinical use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

22 September 2018

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

22 September 2018

Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

22 September 2018

Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

22 September 2018

Apoptosis generates stable fragments of human type I keratins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

22 September 2018

Circulating biomarkers in hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

5 December 2018

Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

5 December 2018

Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

5 December 2018

Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

5 December 2018

‘Fit-for-purpose’ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4648082

5 December 2018

Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900139-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26179201

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/26179201

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/26179201

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/S1470-2045(15)00139-4

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36287599&oldid=2103808755"